Dame Fiona Murray Associate Dean For Innovation Co-Director MIT Innovation Initiative William Porter (1967) Professor of Entrepreneurship Faculty Director Legatum Center MIT Sloan School of Management
What will healthcare look like in the future? What are the technologies that will make the biggest impact in the next decades? In this webcast, you will be able to hear from six MIT academics who will speak to these question in the context of their research. Adding to the perspectives in healthcare, four startups will present lightning talks. Please join us and experience the perspectives arising from MIT and its community.
Contact
Assistant
Phil Budden Senior Lecturer, Technological Innovation, Entrepreneurship, and Strategic Management, MIT Sloan School of Management
Eugene A. Fitzgerald Merton C. Flemings SMA Professor of Materials Science and Engineering
John Carrier Senior Lecturer, System Dynamics MIT Sloan School of Management
Thomas Boyd Director, Oral Care Product Development & Scientific Capabilities, Colgate-Palmolive, Co. Dan Rippy CEO, LiquiGlide
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions  and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has  proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure  exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National  Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients  starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto  University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology)  and to assess the potential for providing algorithm-based services for heart failure patients within Japan.